Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Lilly upgraded its 2025 guidance to between $58 billion to $61 billion, slightly higher than Wall Street expectations by $1 ...

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...